| Jul 1 |
Here’s Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN)
|
| Jun 23 |
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 41% Below Their Intrinsic Value Estimate
|
| Jun 20 |
Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback?
|
| Jun 18 |
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
|
| Jun 17 |
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health
|
| Jun 7 |
KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
|
| Jun 7 |
BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress
|
| Jun 5 |
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
|
| Jun 4 |
BridgeBio data show sustained benefit for achondroplasia drug
|
| May 27 |
BioMarin Pharmaceutical (NASDAQ:BMRN) shareholders have endured a 15% loss from investing in the stock a year ago
|
